|Bid||212.50 x 0|
|Ask||213.40 x 0|
|Day's range||210.50 - 215.10|
|52-week range||139.55 - 245.40|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||24.74|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.
Apellis' (APLS) earnings miss estimates in the fourth quarter of 2021, while revenues surpass expectations.
The European Commission approves Apellis (APLS) and Sobi's Aspaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients. Shares rise.